Recombinant Human Cytochrome P450 2A6 (CYP2A6), partial

1. Results identified a significant association between CYP2A6 rs113288603 and hearing loss symptoms and confirm the role of tobacco smoking in age-related hearing loss mediated by CYP2A6. PMID: 28432340
2. genetic association studies in population in China: Data suggest that SNPs in CYP2C9 and CYP2A6 are associated with hepatotoxicity due to antiepileptic drug valproate in the population studied. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2A6 = cytochrome P450 family 2 subfamily A member 6) PMID: 28273397
3. Our results demonstrated the presence of functional variability in CYP2a6 activities resulting from amino acid substitutions caused by genetic polymorphisms. PMID: 27974382
4. Cynomolgus monkey CYP2A24, which shows 95% amino acid identity to human CYP2A6. PMID: 27625140
5. CYP2A6 rs60823196 and rs138978736 are possible risk factors for serious toxicity in Chinese gastric carcinoma patients treated with S-1 plus oxaliplatin chemotherapy. PMID: 28811232
6. Genetic polymorphisms in CYP2B6 and CYP2A6 explained a significant proportion of variability in EFV plasma concentration in HIV-infected children in a multi-ethnic outpatient clinic. PMID: 28886044
7. In a Mexican Mestizo population, rs1137115(A) and rs4105144(T) in CYP2A6 are associated with cigarette consumption PMID: 28734893
8. CYP2B6/CYP2A6 genotypes were associated with increased reported suicidality among AIDS patients who had been randomly assigned to receive efavirenz-containing regimens in clinical trials. Strength of association varied by race/ethnicity. PMID: 28931220
9. The CYP2A6 gene product plays a major role in the nicotine metabolism pathway, which influences nicotine intake. PMID: 27113016
10. CYP2A6 activity provides information on lung cancer risk that is not captured by smoking history. PMID: 28542511
11. CYP2A6*4 genetic polymorphisms may not strongly affect smoking behavior but may possibly have an effect on nicotine dependence PMID: 26370685
12. CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs, and executive processing in smokers. Because the CYP2A6 effect was seen only in smokers, these data suggest that the rate of nicotine metabolism-and thus the concentration of nicotine presented to the brain over the course of nicotine addiction-shapes brain circuits that, among other functions, compute reward and impulsivity processes. PMID: 27865452
13. a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer. PMID: 27488534
14. Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype PMID: 27902773
15. study demonstrated a strong dose-dependent association between reduced CYP2A6 activity determined by genotypes and reduced risk of lung cancer PMID: 28182203
16. Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank PMID: 27815364
17. drug and the major metabolites were compared with the kinsenoside-cotreated samples. The effect of kinsenoside was negligible on the enzyme activity of all the CYP isozymes tested even though CYP2A6 was slightly inhibited at higher concentrations. PMID: 27322236
18. CYP2A6 gene variants were associated with markedly reduced nicotine and cotinine clearances. PMID: 27035242
19. CYP2A6 polymorphisms are associated with poor response to chemotherapy in gastric cancer. PMID: 26715117
20. Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2A6. PMID: 26648056
21. P450 2A13 is one of the important enzymes that oxidizes polycyclic aromatic hydrocarbons PMID: 26247835
22. It was concluded that, although decreased CYP2A6 AS tended to reduce the risk of bladder cancer in Japanese smokers, no significant association was recognized in this population. PMID: 26725431
23. Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in young smokers. PMID: 25744963
24. Slow nicotine metabolism mediated by CYP2A6 increases risk for tobacco dependence throughout adolescence. PMID: 26644138
25. carcinogen exposure and thereby lower risk of lung cancer. Despite the association between nicotine metabolism (CYP2A6 activity phenotype and diplotypes) and smoking intensity PMID: 26818358
26. lower lung cancer risk observed in CYP2A6 poor metabolizers is partially explained by the strong influence of CYP2A6 genetic polymorphisms on nicotine uptake and metabolism PMID: 26662855
27. phenotypic association studies in population in Nigeria: Data suggest polymorphisms in CYP2A6 exist in the population studied; distribution of CYP2A6 activity is trimodal; influence of age/sex on activity are not significant in this biomarker study. PMID: 26098700
28. No associations were found between the analyzed variants and smoking, however, there was an association among non-smoking subjects between the A allele of rs16969968 and high body mass index. PMID: 26757861
29. Report isolation of CYP2A6 inhibitors from Vernonia cinerea. PMID: 25857233
30. Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. PMID: 26366873
31. CYP2A6 genetic polymorphisms may play important roles in the development of SQCC in Japanese smokers. PMID: 26091970
32. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in nicotine metabolite ratio (NMR) in these study samples. PMID: 26407342
33. differences in genetic variations and haplotypes of CYP2A6, CYP2B6, CYP2C8, and CYP2E1 were observed among ethnic populations. PMID: 24988984
34. We have for the first time demonstrated that the tumor suppressor protein, p53, is a regulator of the CYP2A6 gene. PMID: 26343999
35. CYP2A7 affects CYP2A6 expression by competing for miR-126* binding. PMID: 25710939
36. meta-analysis suggests that CYP2A6 gene polymorphism is associated with daily cigarette consumption. No association with tobacco dependence was found. PMID: 25683822
37. Nicotine dependence among current smokers homozygous for the SLC6A3 10r allele was lower than that of smokers carrying minor alleles, a CYP2A6 polymorphism might mediate this association. PMID: 25526961
38. Genetic variation in CYP2A6 protein influence smoking behaviors to carbon monoxide level. PMID: 25072098
39. The effects of Smilax root on reactive oxygen species and CYP2A6 expression in Hep G2 cells are reported. PMID: 25220663
40. Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. PMID: 24033696
41. secondhand smoke-exposed pregnant women with CYP2A6*1/*4 or *4/*4 genotype had a significantly lower median cotinine level than women with CYP2A6*1/*1 genotype PMID: 24163286
42. Polymorphisms in CYP2A6 gene is associated with Crohn's disease. PMID: 24651583
43. CYP2A6 is located within genes previously associated with chronic obstructive pulmonary disease susceptibility in smokers. PMID: 25006744
44. Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment. PMID: 24127329
45. Results show that variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk. PMID: 24045616
46. study identified seven novel nonsynonymous variants in a population of African American light smokers; each reduced in-vitro CYP2A6 protein expression, enzymatic activity and/or stability, consistent with the associated slow metabolism phenotype. PMID: 24305170
47. CYP2A6 activity was higher in Swedes compared to Koreans (p<0.0001), even among carriers of rapid genotypes. We report major differences in CYP2A6 enzyme activity between Swedes and Koreans mainly due to CYP2A6 genetic variation but not exclusively. PMID: 22850738
48. CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation. They are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum. PMID: 24192532
49. Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation. PMID: 23813797
50. The presence of the CYP2A6 *1/*1 deletion polymorphism might be associated with an increased lung cancer risk, especially for Asians. PMID: 23733493

Show More

Hide All

HGNC: 2610

OMIM: 122720

KEGG: hsa:1548

STRING: 9606.ENSP00000301141

UniGene: Hs.250615